News & monthly recaps
Metabolic peptide news
A monthly UK research-peptide brief. New posts on the second Tuesday of each month — trial read-outs, MHRA position changes, evidence-base shifts.
Subscribe to the monthly brief
One email per month. Research updates, MHRA changes, new pages. No marketing.
Monthly recap
May 2026: GLP-1 research cadence settles, Phase 3 retatrutide eyes Q2 read-out
Published
Monthly UK metabolic-peptide research brief: April → May 2026. TRIUMPH-1 readout window narrows; SURMOUNT-MMO interim slide-pack disclosed; MHRA quiet on tirzepatide labelling.
Monthly recap
April 2026: Retatrutide Phase 3 watch + STEP-HFpEF extension data
Published
March → April 2026 brief: Eli Lilly Q1 earnings call confirms TRIUMPH-1 on-track for H1 2026; semaglutide STEP-HFpEF extension reports durable KCCQ benefit.
Monthly recap
March 2026: SELECT cardiovascular implications crystallise across UK practice
Published
February → March 2026 brief: SELECT trial 30-month follow-up reinforces 20% MACE reduction; UK NICE issues draft positioning for semaglutide in cardio-metabolic prevention.
Field-state assessment
February 2026: Where the incretin class stands at the start of 2026
Published
January → February 2026 brief: A field-state assessment as the new year opens — three MHRA-licensed compounds, two Phase 3 programmes pending, retatrutide approaches its first Phase 3 readout.